Olema Oncology Announces New Preclinical KAT6 Inhibitor Data to be Presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
20 Setembro 2023 - 8:29AM
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq:
OLMA), a clinical-stage biopharmaceutical company focused on the
discovery, development and commercialization of targeted therapies
for women’s cancers, today announced a poster presentation on new
discovery compounds targeting KAT6, an epigenetic target that is
dysregulated in breast and other cancers. The poster, demonstrating
the activity of Olema’s KAT6 inhibitors, will be presented at the
2023 AACR-NCI-EORTC International Conference on Molecular Targets
and Cancer Therapeutics (ANE 2023) taking place October 11-15,
2023, in Boston, Massachusetts.
“We are delighted to share new data at ANE 2023 regarding
Olema’s preclinical program focused on KAT6 inhibition, with novel,
proprietary compounds demonstrating anti-tumor activity in a
variety of ER+ breast cancer models,” said David C. Myles, Ph.D.,
Chief Discovery and Non-Clinical Development Officer of Olema
Oncology. “This new program aligns with our mission of discovering
and developing new targeted therapies for women’s cancers and is
complementary to our efforts focused on the late-stage development
of palazestrant (OP-1250) in advanced or metastatic ER+/HER2-
breast cancer.”
Details of the ANE 2023 poster presentation
are:
Title: |
The discovery of potent KAT6 inhibitors that demonstrate anti-tumor
activity in preclinical models of ER+ breast cancer |
Session: |
Poster Session A |
Poster/Abstract: |
A044 |
Date: |
October 12, 2023 |
Time: |
12:30-4:00 p.m. ET |
The abstract will become available in early October on the
conference website. A copy of the poster will be made available on
Olema’s website under the Science section when it is presented at
the conference on October 12, 2023.
Olema’s KAT6 program has been developed in collaboration with
Aurigene Oncology. In June 2022, Olema signed an exclusive global
licensing agreement with Aurigene to discover, develop and
commercialize novel small molecule inhibitors of KAT6. The combined
Olema / Aurigene team has made progress optimizing compounds
focused on KAT6 inhibition, an important and validated target for
women’s cancers.
About Olema OncologyOlema Oncology is a
clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of targeted therapies for women’s
cancers. Olema’s lead product candidate, palazestrant (OP-1250), is
a proprietary, orally-available small molecule with dual activity
as both a complete estrogen receptor (ER) antagonist (CERAN) and a
selective ER degrader (SERD). It is currently being evaluated both
as a single agent in an ongoing Phase 2 clinical trial, and in
combination with CDK4/6 inhibitors (palbociclib and ribociclib) and
a PI3Ka inhibitor (alpelisib), in patients with recurrent, locally
advanced or metastatic ER-positive (ER+), human epidermal growth
factor receptor 2-negative (HER2-) breast cancer. Palazestrant has
been granted FDA Fast Track designation for the treatment of
ER+/HER2- metastatic breast cancer that has progressed following
one or more lines of endocrine therapy with at least one line given
in combination with a CDK4/6 inhibitor. Olema is headquartered in
San Francisco and has operations in Cambridge, Massachusetts. For
more information, please visit us at www.olema.com, or follow us on
Twitter and LinkedIn.
Forward Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Words such as
“anticipate,” “expect,” “will,” “may,” “goal,” “potential” and
similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) are
intended to identify forward-looking statements. These statements
include those related to Olema’s preclinical program and the
potential beneficial characteristics of palazestrant (OP-1250).
Because such statements deal with future events and are based on
Olema’s current expectations, they are subject to various risks and
uncertainties, and actual results, performance or achievements of
Olema could differ materially from those described in or implied by
the statements in this press release. These forward-looking
statements are subject to risks and uncertainties, including,
without limitation, those discussed in the section titled “Risk
Factors” in Olema’s Quarterly Report on Form 10-Q for the quarter
ended June 30, 2023, and future filings and reports that Olema
makes from time to time with the U.S. Securities and Exchange
Commission. Except as required by law, Olema assumes no obligation
to update these forward-looking statements, including in the event
that actual results differ materially from those anticipated in the
forward-looking statements.
Contact:Geoffrey Mogilner, Vice President, Investor Relations
and Communicationsir@olema.com
Olema Pharmaceuticals (NASDAQ:OLMA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Olema Pharmaceuticals (NASDAQ:OLMA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024